Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 275

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 275
---
,476. The Company has disputed CSL’s payment                                   
 demand and contends that CSL’s demands are baseless under the Framework Supply Agreement, as the minimum purchase commitment                                       
 under the Framework Supply Agreement is conditional upon first obtaining approval of the FDA and the European Medicines Evaluation                                 
 Agency, or EMEA, and other quality and clinical milestones, none of which has occurred. Notwithstanding, CSL claimed to have obtained                              
 a valid German court order in its favor and to endeavor to seek for its enforcement in Israel. Company’s position is that CSL’s                                    
 claim for the payment of the said unshipped minimum purchase commitments lacks any ground under the terms of the Framework Supply                                  
 Agreement and, moreover, that the Company was never served with German judicial documents (e.g., statement of claim) of CSL with                                   
 translations in Hebrew, English or Arabic, as required under the applicable German and international rules of proceeding. Consequently,                            
 based on advice of a German legal counsel, the Company are in the opinion that the legal proceeding initiated by CSL suffered a fundamental                        
 and material procedural error and that no enforceable German judgement could derive thereto. In 2024, the Company has initiated a                                  
 proceeding in Germany to annul said German court’s purported ruling. A hearing to annul the judgement in Germany is scheduled                                      
 for April 2025 and a hearing to discuss the enforcement in Israel is scheduled for June 2025. With respect to the hearing to annul                                 
 the judgment, the judge requested that the parties submit their arguments in writing. The Company submitted its arguments to the German court by way of a brief on 
 April 11, 2025.                                                                                                                                                    |

<div align='center'>F-23</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

The Company’s product has yet
to be approved by FDA and is still in clinical trials and in any event, is not using CSL’s fibrinogen.

From time to time, the Company has
been and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively, “Legal
Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company believes will
have a material adverse impact on the business or financial statements.

| NOTE 10:- | TEMPOR